Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis

• Conditions: Metastatic Melanoma

• Registration Number: NCT05510466
• Lead Sponsor: University Hospital, Montpellier

Brief Summary

Currently, therapeutic options in BRAF mutated melanoma with brain metastasis occurring after achievement of a good control of extracerebral secondary lesions by a first line combined targeted therapy (TT) are limited. In this setting, the addition of an anti PD1 agent to TT may be proposed as a second line strategy. This observational survey aims at investigating the benefit/risk ratio of this triple combination in a small cohort of patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-01
• Status Verified: 2022-01
• Study First Submitted: 2022-01-25
• Study First Submitted QC: 2022-08-19
• Last Update Submitted: 2022-08-19
• Study First Posted: 2022-08-22
• Last Update Posted: 2022-08-22
• Primary Completion: 2023-02-20
• Study Completion: 2023-03-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
comparison between intra and extra cerebral metastasis	day 1	comparison between intra and extra cerebral metastasis

Trial Locations

Locations (1)

Uhmontpellier; 🇫🇷 Montpellier, France